Tezepelumab reduces inflammatory biomarkers in adults with severe chronic rhinosinusitis with nasal polyps with and without comorbid asthma: results from the phase 3 WAYPOINT study Meeting Abstract

publication date

  • November 1, 2025

webpage

published in

start page

  • A112

end page

  • A113

volume

  • 80

issue

  • SUPPL_2